Show simple item record

dc.contributor.authorLuís, Ana Beatriz Mateus D'Avó
dc.contributor.authorSeo, Mikyung Kelly
dc.date.accessioned2022-02-09T10:31:21Z
dc.date.available2022-02-09T10:31:21Z
dc.date.created2022-01-27T11:26:53Z
dc.date.issued2021
dc.identifier.issn1618-7598
dc.identifier.urihttps://hdl.handle.net/11250/2977956
dc.description.abstractDuring the last decade, testing the patient’s biomarker status prior to the administration of corresponding co-dependent therapies has been emerging in clinical practice. These biomarker-guided therapies have promoted the promise of more personalized medicine, with the prescription of the right treatment to the right patient, while avoiding expensive ineffective drugs and adverse drug reactions. Cancer treatments have especially taken advantage of this technology. We assess how the introduction of biomarker tests guiding cancer therapy have affected the premature mortality and survival of cancer patients in Norway. Our findings suggest that, in general, cancer patients have benefited from both biomarker testing and more cancer drugs. Furthermore, we find that the total effect of biomarker testing on 3-year survival decreases as the number of drugs available increases, suggesting that the matching of patients with the appropriate treatment is better when fewer drugs are available.en_US
dc.language.isoengen_US
dc.publisherSpringeren_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleHas the development of cancer biomarkers to guide treatment improved health outcomes?en_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright The Author(s) 2021en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1007/s10198-021-01290-4
dc.identifier.cristin1991161
dc.source.journalEuropean Journal of Health Economicsen_US
dc.source.pagenumber789-810en_US
dc.identifier.citationEuropean Journal of Health Economics. 2021, 22, 789-810.en_US
dc.source.volume22en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal